MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-27-2024
Ampio Pharmaceuticals DSO Ratio 2011-2025 | AMPE
Quarterly DSO Ratio Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.54 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.54 K | 1.54 K | 1.54 K |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B |  USA |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.76 | 2.03 % | $ 790 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.39 | 0.89 % | $ 262 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 212.95 | 1.33 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
20.6 | $ 1.28 | -3.76 % | $ 6.98 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.39 | -0.88 % | $ 8.16 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 25.58 | -1.24 % | $ 1.24 B | USA |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 9.58 | 0.95 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Biogen
BIIB
|
57.9 | $ 174.16 | 0.96 % | $ 25.4 B | USA |
 |
Aytu BioScience
AYTU
|
150 | $ 2.32 | 1.84 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
126 | - | 0.59 % | $ 63 K | USA |
 |
Benitec Biopharma
BNTC
|
141 | $ 12.69 | -2.08 % | $ 522 M | USA |
 |
ChromaDex Corporation
CDXC
|
13.2 | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
134 | $ 573.81 | -1.24 % | $ 43.5 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.28 | -2.62 % | $ 609 M | Israel |
 |
Catalyst Biosciences
CBIO
|
3.24 | $ 15.24 | -0.46 % | $ 1 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.83 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 27.81 | -0.47 % | $ 1.79 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 11.52 | 0.7 % | $ 745 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
157 | - | -5.68 % | $ 8.28 M | USA |
 |
Epizyme
EPZM
|
47.2 | - | - | $ 249 M | USA |
 |
Cerus Corporation
CERS
|
59.2 | $ 2.23 | 3.49 % | $ 412 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |